Clinical trial Recruiting at 2 sites Observational Ages 18 and up

Assessing self-efficacy and well-being in patients with fibrotic interstitial lung disease

Official title: Self-efficacy and Well-being of Patients With Fibrotic Interstitial Lung Disease - an Observational Study

Run by Berner Reha Zentrum AG · NCT06027333 · Data updated 2026-11-12

This study is trying to see how patients with fibrotic interstitial lung disease feel about their quality of life and confidence in managing their health before and after rehabilitation or outpatient care.

More Self-management trials

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment80 (estimated)
SponsorBerner Reha Zentrum AG
Academic / other
Locations2 sites (Bern, Canton of Bern and 1 other locations)
StatusRecruiting
StartedNovember 8, 2023
Main results expectedAugust 30, 2027
Study endsAugust 30, 2028
Registry record updatedSeptember 8, 2026
Trial IDNCT06027333 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older diagnosed with fibrotic interstitial lung disease who are participating in rehabilitation or outpatient care.

Probably not a fit

Patients with cognitive impairments or those who do not speak German may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study invites patients with fibrotic interstitial lung disease (ILD) who are undergoing inpatient rehabilitation or outpatient pulmonary care to participate. Participants will complete questionnaires regarding their quality of life and symptoms at the beginning and end of their rehabilitation or after their second outpatient consultation. The study aims to evaluate changes in self-efficacy and quality of life over time, while also establishing a control cohort for a future feasibility study focused on educational and self-management interventions. Clinical data from routine care and the IIP registry will also be utilized.

Why it matters

Potential benefit: If successful, this study could enhance the understanding of self-efficacy and quality of life in patients with fibrotic ILD, leading to improved patient education and self-management strategies.

How similar studies have gone: While this study is observational and aims to establish a control cohort for future interventions, similar studies have shown promise in improving patient outcomes through self-management and education.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria are:

* For Berner Reha Zentrum only: Diagnosis of a FILD as major indication for pulmonary rehabilitation
* For Inselspital only: Enrolled in Idiopathic interstitial Pneumonia (IIP) cohort study (Nr. 246/15 / PB\_2016-01524) and agreed to further use of data for further research purpose
* Age ≥ 18 years
* Written informed consent

Exclusion criteria are:

* Cognitive inability or insufficient knowledge of project language (German) to follow informed consent or study procedures
* Sarcoidosis

Where it's running

  • Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern
    Bern, Canton of Bern, Switzerland
    Recruiting
  • Berner Reha Zentrum, Rehabilitation & Sports Medicine, Insel Group, University Hospital Berne
    Bern, Heiligenschwendi, Switzerland
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.